ABO and Alzheimer disease: By comparing CSF samples to various amounts of synthetic Aβ42 seeds, authors concluded that Aβ-PMCA allows to detect as little as 3 fmol of AβO, and demonstrated an excellent performance of this assay in discrimination of AD patients from individuals suffering from other neurodegenerative or non-degenerative neurological disorders, with 90% sensitivity and 92% specificity.